NasdaqCM:EVOK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$35.6m

Last Updated

2021/08/05 23:04 UTC

Data Sources

Company Financials +

Executive Summary

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Evoke Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVOK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: EVOK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-3.5%

EVOK

0.8%

US Pharmaceuticals

0.02%

US Market


1 Year Return

-73.2%

EVOK

17.6%

US Pharmaceuticals

33.2%

US Market

Return vs Industry: EVOK underperformed the US Pharmaceuticals industry which returned 17.6% over the past year.

Return vs Market: EVOK underperformed the US Market which returned 33.2% over the past year.


Shareholder returns

EVOKIndustryMarket
7 Day-3.5%0.8%0.02%
30 Day-10.6%3.8%-0.1%
90 Day-30.4%9.1%4.1%
1 Year-73.2%-73.2%22.5%17.6%35.3%33.2%
3 Year-58.3%-58.3%35.2%23.6%61.4%51.3%
5 Year-50.7%-50.7%55.2%35.2%122.2%97.7%

Long-Term Price Volatility Vs. Market

How volatile is Evoke Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evoke Pharma undervalued compared to its fair value and its price relative to the market?

4.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVOK is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: EVOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVOK is overvalued based on its PB Ratio (4.6x) compared to the US Pharmaceuticals industry average (2.9x).


Future Growth

How is Evoke Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

43.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVOK's revenue (96.8% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: EVOK's revenue (96.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Evoke Pharma performed over the past 5 years?

2.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVOK is currently unprofitable.

Growing Profit Margin: EVOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 2.6% per year.

Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.2%).


Return on Equity

High ROE: EVOK has a negative Return on Equity (-178.84%), as it is currently unprofitable.


Financial Health

How is Evoke Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVOK's short term assets ($19.2M) exceed its short term liabilities ($6.2M).

Long Term Liabilities: EVOK's short term assets ($19.2M) exceed its long term liabilities ($5.2M).


Debt to Equity History and Analysis

Debt Level: EVOK's debt to equity ratio (64%) is considered high.

Reducing Debt: EVOK's debt to equity ratio has reduced from 599.6% to 64% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVOK has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 11.8% each year.


Dividend

What is Evoke Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

Dave Gonyer (57 yo)

14.42yrs

Tenure

US$1,171,210

Compensation

Mr. David A. Gonyer, also known as Dave, R.Ph., is a Co-Founder of Evoke Pharma, Inc. and has been its Chief Executive Officer and President since March 2007. Mr. Gonyer held senior management positions bo...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD555.00K).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EVOK's management team is seasoned and experienced (7.7 years average tenure).


Board Members

Experienced Board: EVOK's board of directors are seasoned and experienced ( 14.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31%.


Top Shareholders

Company Information

Evoke Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evoke Pharma, Inc.
  • Ticker: EVOK
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$35.609m
  • Shares outstanding: 32.37m
  • Website: https://www.evokepharma.com

Number of Employees


Location

  • Evoke Pharma, Inc.
  • 420 Stevens Avenue
  • Suite 370
  • Solana Beach
  • California
  • 92075
  • United States

Listings


Biography

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/05 23:04
End of Day Share Price2021/08/05 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.